United States · Platforms & data · The Motley Fool

Novo's CagriSema Delivered 25% Weight Loss in Women. Could It Help Turn Around the Beaten-Down Stock?

Published by The Motley Fool · United States 54 min ago

Its leading investigational drug demonstrated relatively high levels of weight loss in a late-stage clinical trial.

Read the full article on The Motley Fool Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.fool.com)

Also worth reading

Bank regulator to effect GENIUS Act from January 18 next year

Musk says he’s exploring a SpaceX-Tesla megamerger. What would a combined company be worth?

Range Financial Group LLC Buys 112,112 Shares of Onespan Inc $OSPN

Best Tech Stocks Right Now

Why is Stifel Financial stock rallying today?

Why Did CRWV, SMR, FRMI Stocks Plunge To 52-Week Lows Today?